Kazuhiro Yoshinaga

Dr. Kazuhiro Yoshinaga

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2025 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
HMHideaki Mabuchi
Hideaki Mabuchi
TKToshiaki Kawano
Toshiaki Kawano
RGRyosuke Gobaru
Ryosuke Gobaru
KYKazuhiro Yoshinaga
Kazuhiro Yoshinaga
AUAyako Ueo
Ayako Ueo
THTakashi Hirano
Takashi Hirano
Vaccination is the most potent and cost-effective way to combat the threat of influenza outbreaks. Strategies to enhance influenza vaccine immunogenicity include the use of high antigen dose vaccines and the inclusion of an appropriate adjuvant. The benefits of adjuvants include enhanced immunogenicity, antigen-sparing, and greater duration of protection. However, adjuvants can increase vaccine reactogenicity and may adversely impact vaccine safety; hence, both risks and benefits need to be carefullyconsidered when adding adjuvants to a vaccine. In this study, we examined the efficacy of aluminum hydroxide (alum), a representative Th2-type adjuvant, and CpG oligodeoxynucleotide (CpG ODN), a Toll-like receptor 9 agonist, as adjuvants for the influenza vaccine in mice. BALB/c micewere transnasally administered recombinant hemagglutinin (HA) H1N1 vaccine formulated with or without alum and/or CpG ODN. The double adjuvanted vaccine was effective for inducing B cells and NK cells in the lymph node, and B cells in the lung after infection. Additionally, double adjuvants were observed to be effective for antibody production and immune cell activation in various organs, in addition to suppressing side effects. Intranasally-administered double adjuvanted vaccines may serve as an effective means to prevent infection and to reduce side effects of the influenza vaccine.

13 March 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
KYKazuhiro Yoshinaga
Kazuhiro Yoshinaga
THTakashi Hirano
Takashi Hirano
SUShingo Umemoto
Shingo Umemoto
YKYoshinori Kadowaki
Yoshinori Kadowaki
TMTakayuki Matsunaga
Takayuki Matsunaga
MSMasashi Suzuki
Masashi Suzuki
Background/Objectives: Acute otitis media is a common pediatric infection caused primarily by nontypeable Haemophilus influenzae. With rising antibiotic resistance, vaccines are essential for combating this public health issue. Although the PD-1/PD-L1 pathway has been extensively studied for its role in tumor immunity, its impact on mucosal immunity, particularly in vaccine responses, is unclear. Methods: BALB/c mice were intranasally immunized with nontypeable H. influenzae outer membrane protein and treated with anti-PD-L1 antibodies. Immune responses were evaluated in middle ear mucosa (MEM), the cervical lymph node, and the spleen using an enzyme-linked immunosorbent assay, an enzyme-linked immunospot assay, and flow cytometry. The effects on CD4+ T cells, T follicular helper (Tfh) cells, and B-cell differentiation were analyzed. Results: Anti-PD-L1 antibody treatment increased CD3+CD4+CD185+ (CXCR5+) Tfh cells in MEM, which play a crucial role in supporting B-cell activation and antibody production. This correlated with a significant increase in IgA- and IgG-producing cells in MEM, which enhanced local bacterial clearance. Although B-cell activation and differentiation into plasmablasts were observed in MEM, no significant changes were noted in the cervical lymph node and spleen, suggesting a localized enhancement of mucosal immunity. Conclusions: Anti-PD-L1 antibodies promoted Tfh cell expansion and B-cell differentiation in MEM, leading to enhanced antibody production and improved bacterial clearance. These findings suggest that PD-L1 blockade can potentiate mucosal vaccine-induced immunity by strengthening local humoral responses. This supports its potential application in developing intranasal vaccines for acute otitis media.